Nevro
A global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain.
Launch date
Employees
Market cap
€173m
Enterprise valuation
€144m (Public information from Sep 2024)
Share price
$5.82 NVRO
Redwood City California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 362m | 387m | 406m | 425m | 403m | 412m | 434m |
| % growth | (7 %) | 7 % | 5 % | 5 % | (5 %) | 2 % | 5 % |
| EBITDA | (62.9m) | (70.9m) | (204m) | (74.2m) | (19.9m) | (11.4m) | 6.1m |
| % EBITDA margin | (17 %) | (18 %) | (50 %) | (17 %) | (5 %) | (3 %) | 1 % |
| Profit | (83.1m) | (131m) | 3.0m | (92.2m) | (101m) | (96.9m) | (79.8m) |
| % profit margin | (23 %) | (34 %) | 1 % | (22 %) | (25 %) | (24 %) | (18 %) |
| EV / revenue | 15.7x | 6.8x | 3.0x | 1.6x | 0.4x | 0.5x | 0.5x |
| EV / EBITDA | -90.4x | -36.9x | -6.0x | -9.0x | -8.8x | -18.1x | 33.3x |
| R&D budget | 45.6m | 47.7m | 53.1m | 54.4m | - | - | - |
| R&D % of revenue | 13 % | 12 % | 13 % | 13 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$5.5m | Series A | ||
$21.8m | Series A | ||
£58.0m | Series B | ||
$48.0m | Series C | ||
$50.0m | Debt | ||
| N/A | N/A | IPO | |
| N/A | $173m | Post IPO Debt | |
* | N/A | $200m | Post IPO Convertible |
| Total Funding | €138m | ||
